Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier


    David Ross


    Devendra Hiwase Michael Osborn              


    Session 4: CML Related Topics
    Chair: A/Prof Agnes Yong

    • Management of Myelofibrosis
      (Dr David Ross)
    • MDS/MPN Overlap Syndrome
      (Dr Devendra Hiwase)
    • Pediatric CML
      (Dr Michael Osborn)



    David Ross



    Management of Myelofibrosis
    Dr David Ross, SA Pathology / Universities of Adelaide and South Australia

    • COMFORT trials
    • Dosing guidance
    • Important toxicities
    • Interrupting or stopping treatment
    • Patient population outside COMFORT trials
      • INT-1 and low-risk
      • Pre- and post-transplant
    • Other JAK inhibitors



    Devendra Hiwase  

    MDS/MPN Overlap Syndrome
    Dr Devendra Hiwase, SA Pathology / Royal Adelaide Hospital / SAHMRI

    • How is MDS diagnosed?
    • MDS/MPN overlap
    • MDS/MPN's: WHO subtypes
    • CMML: diagnostic criteria
    • Cytogenetic abnomalities in CMML
    • Common genetic mutations in CMML
    • Current therapeutic strategies in CMML
    • WHO diagnostic criteria for aCML
    • Diagnosis of aCML
    • Treatment algorithms for aCML
    • Chronic neutrophilic leukemia

    Michael Osborn


    Pediatric CML
    Dr Michael Osborn - Royal Adelaide Hospital

    • CML is different in children and adults
    • Clinical presentation is different in children and adults
    • Adult prognostic scores do not apply to children
    • Imatinib in children with CML
    • Dasatinib in children with CML
    • Nilotinib in children with CML
    • What about stem cell transplant?
    • Can we stop TKI in children with deep response?